难治性痛风发作符合白介素-1抑制治疗指征者在私人执业中罕见:依据现行EMA批准标准
基于法国GOSPEL横断面队列1003例痛风患者,评估对秋水仙碱、NSAIDs和全身糖皮质激素存在禁忌或不耐受者是否符合IL-1抑制治疗(canakinumab)的欧洲批准标准。结果仅1%患者符合一线IL-1治疗的确定指征,21.7%存在至少需谨慎使用标准治疗的情况;基线发作患者中23.4%在第3天疼痛评分仍≥4/10,但仅9例符合二线IL-1治疗指征。结论认为尽管相当数量患者无标准抗炎治疗选择,但符合现行欧洲批准IL-1抑制治疗者罕见。
要点
- 1003例痛风患者中仅10例(1%)符合一线IL-1抑制治疗确定指征。
- 218/1003例(21.7%)对标准治疗药物至少存在需谨慎使用的情况。
- 基线发作的487例中114例(23.4%)第3天疼痛评分仍≥4/10,仅9例符合二线IL-1治疗指征。
核心结论
- 尽管相当数量痛风患者无标准抗炎治疗选择,但依据现行欧洲批准标准符合IL-1抑制治疗者罕见。
研究设计与样本
- 法国GOSPEL横断面队列纳入1003例痛风患者,评估对秋水仙碱、NSAIDs和全身糖皮质激素的禁忌或不耐受情况。
- 按欧洲产品特征摘要将患者分类为确定符合一线IL-1抑制治疗(canakinumab)、潜在符合或不符合,并评估发作期间因疗效不足的二线 eligibility。
主要发现
- 确定符合一线IL-1治疗者10例(1%),另有9例对所有标准治疗存在禁忌但过去12个月发作<3次。
- 218/1003例(21.7%)对标准治疗至少存在需谨慎使用的情况。
- 基线发作的487例中,114例(23.4%)第3天疼痛数字评分仍≥4/10,其中1例无法接受进一步标准治疗药物。
- 上述114例中仅9例过去一年发作≥3次并符合二线IL-1抑制治疗指征。
关键数值与推荐
- 一线IL-1抑制治疗确定指征:对标准治疗药物存在禁忌/不耐受且每年至少3次发作,无其他抗炎选择。
- 二线IL-1抑制治疗指征:发作期间因标准治疗疗效不足且过去一年发作≥3次。
临床怎么用
- 临床中符合现行欧洲批准IL-1抑制治疗标准的难治性痛风发作患者比例很低,需严格按指征筛选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective was to determine the proportion of patients with difficult-to-treat or difficult-to-prevent acute gout attacks eligible for IL-1 inhibition. METHODS: Participants included in the French cross-sectional GOSPEL cohort (n = 1003 gout patients) were examined for contraindications and intolerance to standard of care (SoC) drugs of gout flares (colchicine, non-steroidal anti-inflammatory drugs and systemic glucocorticoids). Patients were classified as definitely eligible for first-line IL-1 inhibition (canakinumab) according to European summary of product characteristics (contraindications/intolerance to SoC and at least three flares per year) without any other anti-inflammatory options (contraindications/intolerance only), or potentially eligible (precaution of use). Eligibility to receive IL-1 during an on-going flare related to insufficient efficacy was assessed (second-line eligibility). RESULTS: Definite first-line eligibility for IL-1 therapy was found in 10 patients (1%) and contraindication to all SoC therapies in nine patients who had presented <3 flares in the past 12 months. At least precaution of use for SoC therapies was noted for 218/1003 patients (21.7%). Of 487 patients experiencing flares at baseline, 114 (23.4%) were still experiencing pain scored ⩾4/10 numeric scale on day 3, one of whom could not receive further SoC drugs. Only nine of them had three or more flares in the past year and were eligible for second-line IL-1 inhibition. CONCLUSION: Despite significant numbers of patients without any SoC anti-inflammatory therapeutic options for gout flares, eligibility for IL-1 inhibition therapy according to current European approval is rare.
引用
- Pascart T, Norberciak L, Ea HK, et al. Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Rheumatology (Oxford). 2019. PMID: 31177284. doi:10.1093/rheumatology/kez203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。